Evidence map›Paper›PMID 40890032›Full record

ArticleEmerging microbes & infections2025

Development of

Yawen Liu, Chunlong Chen, Binfan Liao, Xiuzhu Geng, Weijin Huang, Jianhui Nie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yawen LiuDivision of HIV/AIDS and Sex-Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
Chunlong ChenThe Sixth Laboratory, National Vaccine & Serum Institute (NVSI), Beijing, People's Republic of China.
Binfan LiaoSchool of Life Science and Bio-pharmaceutics, Shenyang Pharmaceutical University, Shenyang, People's Republic of China.
Xiuzhu GengDivision of HIV/AIDS and Sex-Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
Weijin HuangDivision of HIV/AIDS and Sex-Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
Jianhui NieDivision of HIV/AIDS and Sex-Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.ORCID 0000-0002-1474-0427

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The New World alphaviruses, including Eastern Equine Encephalitis Virus (EEEV), Western Equine Encephalitis Virus (WEEV), and Venezuelan Equine Encephalitis Virus (VEEV), are known to cause neurological diseases that pose a significant threat to public health concerns and bioterrorism preparedness challenges due to their potential for aerosol transmission. Currently, no FDA-approved vaccines or antiviral drugs are available for humans, although ongoing studies are exploring potential solutions. Most vaccine evaluation methods rely on live virus models, which require handling in biosafety level 3 (BSL-3) facilities. In this study, we constructed pseudoviruses for NW alphaviruses using the vesicular stomatitis virus (VSV) system by expressing the glycoproteins E3-E2-E1 on the surface of the VSV vector.

Indexed as

AlphavirusAlphavirus InfectionsNeutralization TestsVesiculovirusAnimalsAntibodies, NeutralizingAntibodies, ViralCell LineChlorocebus aethiopsDisease Models, AnimalEncephalitis Virus, Eastern EquineEncephalitis Virus, Venezuelan EquineFemaleGenetic VectorsHumansMiceAntibodies, NeutralizingAntibodies, ViralViral Vaccinesanimal modelbioluminescence imagingDNA vaccineNew World alphavirusesPseudovirus

Identifiers

PMID40890032
PMCPMC12444932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.